Found 352 oncology trials
A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations. We would like to rely on Advarra as the …
The purpose of this study is to test the study drug, PC14586 alone and in combination with pembrolizumab in patients with an advanced solid tumor with a TP53 Y220C alteration who have gone through one or more anticancer therapies and are not responding. PC14586 will be tested at different doses …
Please refer to Protocol Section 5 (Trial Objectives) Please refer to Protocol 6.2.1 (Phase 1 Primary Endpoints) and Protocol Section 6.2.4 (Phase 2 Primary Endpoints) Please refer to Protocol 6.2.2 (Phase 1 Secondary Endpoint) and Protocol Section 6.2.5 (Phase 2 Secondary Endpoints)
This is a randomized phase 2 open label study of sacituzumab govitecan +/- pembrolizumab for patients with PD-L1-negative (PD-L1-) metastatic triple negative breast cancer (TNBC), who have not received prior therapy for metastatic breast cancer and who have not received a prior PD-1/L1 inhibitor
This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation.
To examine whether the addition of nivolumab, a monoclonal antibody specific for human programmed death-1 (PD-1) receptor expressed on T cells, after chemoradiation can provide a survival benefit in patients with locally advanced high-risk anal cancer
This is a first-in-human (FIH), open label Phase 1/1b study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens. Phase 1b will evaluate …
A Phase 1/2a dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with advanced metastatic or unresectable solid cancer that is refractory to or has progressed during or after at least 1 line of appropriate prior systemic anti-cancer therapy, or prior standard of care therapy …
The purpose of this study is to determine if two surgical procedures, the usual approach of removing the fallopian tubes and ovaries and the other approach of removing the fallopian tubes at this time with the plan to remove the ovaries at a later time, are no different for ovarian …
This is a screening study to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
